A regulatory role for CD72 expression on B cells in systemic lupus erythematosus

详细信息    查看全文

• 作者：Zahava Vadasz ; MD ; PhD^a ; ^d ; Tharwat Haj ; PhD^a ; ^d ; Alexandra Balbir ; MD^b ; ^d ; Regina Peri ; MD^a ; ^d ; Itzhak Rosner ; MD^c ; ^d ; Gleb Slobodin ; MD^c ; ^d ; Aharon Kessel ; MD^a ; ^d ; Elias Toubi ; MD^a ; ^d ; ^{elias.toubi@b-zion.org.il" class="auth_mail}
• 关键词：CD72 ; SLE ; Autoimmunity ; Regulation
• 刊名：Seminars in Arthritis and Rheumatism
• 出版年：June 2014
• 年：2014
• 卷：43
• 期：6
• 页码：767-771
• 全文大小：635 K

文摘

B regulatory cells and their regulatory products/markers, such us semaphorin 3A (sema3A) and its receptor NP-1, Fc纬IIB, IL-10, and others, act at the very base of self-tolerance, maintenance, and prevention of autoimmune disease development.

Objectives

The aim of the present study was to assess the involvement of CD72, a regulatory receptor on B cells, in systemic lupus erythematosus (SLE). In addition, the potential of soluble sema3A in enhancing the expression of CD72 on B cells of SLE patients was investigated.

Results

CD72 expression on activated B cells of SLE patients was significantly lower than that of normal controls. This lower expression of CD72 in SLE patients correlated inversely with SLE disease activity and was associated with lupus nephritis, the presence of anti-dsDNA antibodies, and low levels of complement. Co-culture of purified B cells from healthy controls with condition-media containing recombinant sema3A resulted in significant enhancement of CD72. Similar enhancement of CD72 on activated B cells from SLE patients, though significant, was still lower than in normal individuals.

Conclusions

The lower expression of CD72 on activated B cells from SLE patients correlates with SLE disease activity, lupus nephritis, the presence of anti-dsDNA antibodies, and low levels of complement. The improvement of CD72 expression following the addition of soluble semaphorin 3A suggests that CD72 may be useful as a biomarker to be followed during the treatment of SLE.